
    
      The MIDAB-Follow-up trial will examine the difference in survival and neurodevelopmental
      impairment of infants who were depressed at birth and enrolled in MIDAB trial. The difference
      in survival and neurodevelopmental impairment in infants who received UCM and ICC will be
      assessed using standardized neurological and developmental assessment tools at 22-26 months
      of age.
    
  